News InspireMD, Inc.

Equities

NSPR

US45779A8466

Real-time Estimate Cboe BZX Other stock markets 11:19:29 2024-04-25 am EDT			5-day change	1st Jan Change
1.89 ^USD	+2.16%		-11.25%	-32.38%

Mar. 06	Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Mar. 06	Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	Mar. 26	AQ
Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	Mar. 06	MT
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	Mar. 06	AQ
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	Feb. 28	AQ
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	Feb. 12	AQ
InspireMD Gets CE Mark Recertification From the European Union	Jan. 31	MT
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	Jan. 31	AQ
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	Jan. 03	AQ
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America	Jan. 03	CI
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System	Dec. 20	AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	Nov. 27	AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	Nov. 27	CI
Transcript : InspireMD, Inc., Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M	Nov. 06	MT
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 06	AQ
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
InspireMD to Participate in Upcoming November Investor Conferences	Nov. 02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News InspireMD, Inc.

Equities

NSPR

US45779A8466

Summary

Filters